Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + trastuzumab + docetaxel with MYJ1633 in recurrent unresectable or metastatic HER2-positive breast cancer
KCT0005812Phase 2Completed
- Sponsor
- ImmunisBio
- Start
- Oct 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab, trastuzumab, docetaxel, MYJ1633 in breast cancer, sponsored by ImmunisBio. Started Oct 2021; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0005812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005812.